# A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

> **NCT03691623** · PHASE2 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 179 (actual)

## Conditions studied

- RSV Infection

## Interventions

- **DRUG:** EDP-938 Dose 1
- **DRUG:** EDP-938 Dose 2
- **DRUG:** Placebo
- **DRUG:** EDP-938 Dose 3
- **DRUG:** EDP-938 Dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03691623
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-15
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-10-18
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691623, "A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03691623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*